We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why
Read MoreHide Full Article
Shares of Keros Therapeutics (KROS - Free Report) , a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing in the ongoing mid-stage study of its pipeline candidate, cibotercept (KER-012), to treat patients with pulmonary arterial hypertension (PAH), a kind of lung disease.
Keros Therapeutics’ decision was based on unexpected adverse pericardial effusion events that were observed during the study's safety review by an independent data monitoring committee (DMC). Cibotercept is an investigational modified ActRIIB fusion protein.
The phase II TROPOS study is evaluating three doses of cibotercept (1.5 mg/kg, 3 mg/kg and 4.5 mg/kg) in combination with background therapy to treat PAH patients. After consulting with the DMC, Keros Therapeutics initially chose to suspend dosing in the 3 mg/kg and 4.5 mg/kg treatment arms of the TROPOS study while continuing dosing in the 1.5 mg/kg arm. However, earlier this month, the company announced the suspension of dosing in the 1.5 mg/kg and placebo arms as well, following the observation of new adverse pericardial effusion events during an ongoing safety review.
In the past year, KROS shares have plunged 79.8% compared with the industry’s 12% decline.
Image Source: Zacks Investment Research
Keros Therapeutics has informed investigators and certain regulatory authorities, including the FDA, of this decision and is in the process of notifying other relevant regulatory bodies. The TROPOS study is being concluded ahead of schedule, with patients expected to be monitored through their end-of-trial visits. The company still plans to present top-line data from all treatment arms of the mid-stage study in the second quarter of 2025.
Other Developmental Programs in KROS’ Pipeline
Keros has two other novel investigational candidates in its clinical-stage pipeline, elritercept (KER-050), ActRIIA fusion protein, and KER-065, a selective activin receptor ligand trap.
Elritercept is currently being evaluated in two ongoing phase II studies to treat patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) and patients with myelofibrosis. KROS is also gearing up to initiate enrollment in a planned, registrational phase III study of elritercept called RENEW to treat adult patients with transfusion-dependent anemia with very low-, low-, or intermediate-risk MDS. Last month, the company also signed a global licensing agreement with Takeda to advance the development and commercialization of elritercept.
Keros Therapeutics’ KER-065 is being developed for the treatment of obesity and neuromuscular diseases. Currently, a phase I study is evaluating single and multiple ascending doses of thecandidate in healthy adults. Top-line data is anticipated in the first quarter of 2025. Upon completing this early-stage study, KROS plans to initiate a proof-of-concept study of KER-065 in obese patients.
In the past 30 days, Castle Biosciences’ earnings estimates for 2024 have increased from 34 cents to 39 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 16.3%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 30 days, estimates for BioMarin Pharmaceutical’s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have decreased from $4.05 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 11.9%.
BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%.
In the past 30 days, estimates for CytomX Therapeutics’ 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In the past three months, shares of CytomX Therapeutics have lost 22.4%.
CTMX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why
Shares of Keros Therapeutics (KROS - Free Report) , a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing in the ongoing mid-stage study of its pipeline candidate, cibotercept (KER-012), to treat patients with pulmonary arterial hypertension (PAH), a kind of lung disease.
Keros Therapeutics’ decision was based on unexpected adverse pericardial effusion events that were observed during the study's safety review by an independent data monitoring committee (DMC). Cibotercept is an investigational modified ActRIIB fusion protein.
The phase II TROPOS study is evaluating three doses of cibotercept (1.5 mg/kg, 3 mg/kg and 4.5 mg/kg) in combination with background therapy to treat PAH patients. After consulting with the DMC, Keros Therapeutics initially chose to suspend dosing in the 3 mg/kg and 4.5 mg/kg treatment arms of the TROPOS study while continuing dosing in the 1.5 mg/kg arm. However, earlier this month, the company announced the suspension of dosing in the 1.5 mg/kg and placebo arms as well, following the observation of new adverse pericardial effusion events during an ongoing safety review.
In the past year, KROS shares have plunged 79.8% compared with the industry’s 12% decline.
Image Source: Zacks Investment Research
Keros Therapeutics has informed investigators and certain regulatory authorities, including the FDA, of this decision and is in the process of notifying other relevant regulatory bodies. The TROPOS study is being concluded ahead of schedule, with patients expected to be monitored through their end-of-trial visits. The company still plans to present top-line data from all treatment arms of the mid-stage study in the second quarter of 2025.
Other Developmental Programs in KROS’ Pipeline
Keros has two other novel investigational candidates in its clinical-stage pipeline, elritercept (KER-050), ActRIIA fusion protein, and KER-065, a selective activin receptor ligand trap.
Elritercept is currently being evaluated in two ongoing phase II studies to treat patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) and patients with myelofibrosis. KROS is also gearing up to initiate enrollment in a planned, registrational phase III study of elritercept called RENEW to treat adult patients with transfusion-dependent anemia with very low-, low-, or intermediate-risk MDS. Last month, the company also signed a global licensing agreement with Takeda to advance the development and commercialization of elritercept.
Keros Therapeutics’ KER-065 is being developed for the treatment of obesity and neuromuscular diseases. Currently, a phase I study is evaluating single and multiple ascending doses of thecandidate in healthy adults. Top-line data is anticipated in the first quarter of 2025. Upon completing this early-stage study, KROS plans to initiate a proof-of-concept study of KER-065 in obese patients.
Keros Therapeutics, Inc. Price and Consensus
Keros Therapeutics, Inc. price-consensus-chart | Keros Therapeutics, Inc. Quote
KROS’ Zacks Rank & Other Stocks to Consider
Keros Therapeutics currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the sector are Castle Biosciences (CSTL - Free Report) , BioMarin Pharmaceutical (BMRN - Free Report) and CytomX Therapeutics (CTMX - Free Report) . While CSTL and BMRN currently sporta Zacks Rank #1 (Strong Buy), CTMX carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, Castle Biosciences’ earnings estimates for 2024 have increased from 34 cents to 39 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 16.3%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 30 days, estimates for BioMarin Pharmaceutical’s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have decreased from $4.05 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 11.9%.
BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%.
In the past 30 days, estimates for CytomX Therapeutics’ 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In the past three months, shares of CytomX Therapeutics have lost 22.4%.
CTMX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.